291 related articles for article (PubMed ID: 28244808)
21. Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment.
Seripa D; Latina P; Fontana A; Gravina C; Lattanzi M; Savino M; Gallo AP; Melchionda G; Santini SA; Margaglione M; Copetti M; di Mauro L; Panza F; Greco A; Pilotto A
Pain Med; 2015 Oct; 16(10):2012-23. PubMed ID: 25989235
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
[TBL] [Abstract][Full Text] [Related]
23. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
25. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
26. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6 phenotype-specific codeine population pharmacokinetics.
Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
[TBL] [Abstract][Full Text] [Related]
28. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
29. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.
Tyndale RF; Droll KP; Sellers EM
Pharmacogenetics; 1997 Oct; 7(5):375-9. PubMed ID: 9352573
[TBL] [Abstract][Full Text] [Related]
30. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.
Mas S; Gassó P; Torra M; Bioque M; Lobo A; González-Pinto A; Olmeda MS; Corripio I; Vieta E; Castro-Fornieles J; Rodriguez-Jimenez R; Bobes J; Usall J; Llerena A; Saiz-Ruiz J; Bernardo M; Lafuente A; PEPs Group
Eur Neuropsychopharmacol; 2017 Jul; 27(7):647-656. PubMed ID: 28389049
[TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of oxycodone.
Lugo RA; Kern SE
J Pain Palliat Care Pharmacother; 2004; 18(4):17-30. PubMed ID: 15760805
[TBL] [Abstract][Full Text] [Related]
32. Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism.
Deodhar M; Turgeon J; Michaud V
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575542
[TBL] [Abstract][Full Text] [Related]
33. Impact of CYP2D6 genotype on postoperative tramadol analgesia.
Stamer UM; Lehnen K; Höthker F; Bayerer B; Wolf S; Hoeft A; Stuber F
Pain; 2003 Sep; 105(1-2):231-8. PubMed ID: 14499440
[TBL] [Abstract][Full Text] [Related]
34. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.
Grönlund J; Saari TI; Hagelberg N; Neuvonen PJ; Olkkola KT; Laine K
Antimicrob Agents Chemother; 2011 Mar; 55(3):1063-7. PubMed ID: 21173180
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
[TBL] [Abstract][Full Text] [Related]
36. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
[TBL] [Abstract][Full Text] [Related]
37. Morphine or oxycodone in cancer pain?
Heiskanen TE; Ruismäki PM; Seppälä TA; Kalso EA
Acta Oncol; 2000; 39(8):941-7. PubMed ID: 11207001
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
39. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.
Klimas R; Witticke D; El Fallah S; Mikus G
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):517-28. PubMed ID: 23488585
[TBL] [Abstract][Full Text] [Related]
40. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
de Leon J; Dinsmore L; Wedlund P
J Clin Psychopharmacol; 2003 Aug; 23(4):420-1. PubMed ID: 12920424
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
